Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Clinical trial NCT07288359 · RECRUITING

Trial details

NCT number: NCT07288359
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced HR+/HER2- Breast Cancer Advanced CCNE1-amplified Solid Tumors Metastatic Castration-resistant Prostate Cancer

Start date: 2025-12-29
Primary completion: 2031-05-09
Enrollment: 205

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.